UroGen Pharma Ltd. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting a significant year-over-year increase in revenue alongside a continued net loss for the second quarter.

Key Highlights

  • Revenue nearly tripled year-over-year: Revenue for the three months ended June 30, 2026 was $72,456 thousand, compared to $24,215 thousand in the same period of 2025.
  • Net loss narrowed significantly: Net loss for Q2 2026 was $14,351 thousand, compared to a net loss of $49,940 thousand in Q2 2025.
  • Six-month revenue more than doubled: Revenue for the six months ended June 30, 2026 was $123,415 thousand, versus $44,469 thousand for the same period in 2025.
  • Shareholders' deficit widened: Total shareholders' deficit was $(132,396) thousand as of June 30, 2026, compared to $(105,474) thousand as of December 31, 2025.
  • Accumulated deficit increased: The accumulated deficit reached $(997,641) thousand as of June 30, 2026, up from $(959,716) thousand at December 31, 2025.
  • Long-term debt rose: Long-term debt was $188,734 thousand as of June 30, 2026, compared to $122,210 thousand at December 31, 2025.
  • Shares outstanding: As of July 28, 2026, the registrant had 48,880,564 ordinary shares outstanding.

UroGen Pharma Q2 2026: Revenue Growth and Continued Net Loss

According to the filing, UroGen Pharma Ltd. (Nasdaq: URGN), an Israeli-incorporated company with principal offices in Princeton, New Jersey, reported revenue of $72,456 thousand for the three months ended June 30, 2026, a substantial increase from $24,215 thousand in the comparable prior-year quarter. Gross profit for Q2 2026 was $65,884 thousand, compared to $20,665 thousand in Q2 2025. The company reported operating income of $111 thousand for the second quarter of 2026, contrasting with an operating loss of $(41,448) thousand in the same period of 2025.

Despite improved operating results, the company disclosed a net loss of $14,351 thousand for Q2 2026, driven in part by financing costs on the prepaid forward obligation of $(4,545) thousand, interest expense on long-term debt of $(4,887) thousand, and income tax expense of $(5,629) thousand. For the six months ended June 30, 2026, the net loss was $37,925 thousand, compared to $93,783 thousand for the same period in 2025. Net loss per ordinary share (basic and diluted) was $(0.28) for Q2 2026, versus $(1.05) in Q2 2025.

The balance sheet as of June 30, 2026 showed total assets of $252,590 thousand, up from $200,455 thousand at December 31, 2025. Accounts receivable, net increased to $88,757 thousand from $33,082 thousand over the same period. Total liabilities rose to $384,986 thousand from $305,929 thousand, reflecting growth in long-term debt and the prepaid forward obligation, which stood at $125,135 thousand. The company is classified as a non-accelerated filer and a smaller reporting company, according to the filing.

What Was Disclosed

UroGen Pharma filed its quarterly report covering the period ended June 30, 2026, disclosing substantially higher revenue and a reduced net loss compared to the prior year, alongside an expanded balance sheet with increased debt and a widened shareholders' deficit.